載入...
Clinical Development of Phosphatidylinositol-3 Kinase Pathway Inhibitors
The PI3K pathway is the most commonly altered in human cancer. Several recent phase I studies with therapeutic inhibitors of this pathway have shown that pharmacological inhibition of PI3K in humans is feasible and overall well tolerated. Furthermore, there has already been clinical evidence of anti...
Na minha lista:
| 主要作者: | |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2010
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3221735/ https://ncbi.nlm.nih.gov/pubmed/20593313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/82_2010_54 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|